CN113244387A - 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 - Google Patents

针对降钙素基因相关肽的拮抗剂抗体及其使用方法 Download PDF

Info

Publication number
CN113244387A
CN113244387A CN202110564918.9A CN202110564918A CN113244387A CN 113244387 A CN113244387 A CN 113244387A CN 202110564918 A CN202110564918 A CN 202110564918A CN 113244387 A CN113244387 A CN 113244387A
Authority
CN
China
Prior art keywords
antibody
cgrp
headache
subject
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110564918.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·比加尔
S·沃尔特
H·斯特恩
M·常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
Original Assignee
Teva Pharmaceuticals International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54141465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113244387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals International GmbH filed Critical Teva Pharmaceuticals International GmbH
Publication of CN113244387A publication Critical patent/CN113244387A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CN202110564918.9A 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 Pending CN113244387A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461968897P 2014-03-21 2014-03-21
US61/968,897 2014-03-21
US201462083809P 2014-11-24 2014-11-24
US62/083,809 2014-11-24
US201562119778P 2015-02-23 2015-02-23
US62/119,778 2015-02-23
CN201580025693.2A CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580025693.2A Division CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Publications (1)

Publication Number Publication Date
CN113244387A true CN113244387A (zh) 2021-08-13

Family

ID=54141465

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010893685.2A Pending CN111973740A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN201580025693.2A Pending CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN202110564918.9A Pending CN113244387A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202010893685.2A Pending CN111973740A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN201580025693.2A Pending CN106456759A (zh) 2014-03-21 2015-03-20 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Country Status (27)

Country Link
US (3) US9896502B2 (enExample)
EP (2) EP3119431B1 (enExample)
JP (5) JP6568099B2 (enExample)
KR (4) KR20240146107A (enExample)
CN (3) CN111973740A (enExample)
AU (1) AU2015230933B2 (enExample)
BR (1) BR112016021423A2 (enExample)
CA (1) CA2943551A1 (enExample)
CL (1) CL2016002375A1 (enExample)
DK (1) DK3119431T3 (enExample)
EA (1) EA201691787A1 (enExample)
ES (1) ES2974803T3 (enExample)
FI (1) FI3119431T3 (enExample)
HR (1) HRP20240159T1 (enExample)
HU (1) HUE065397T2 (enExample)
IL (2) IL247853B (enExample)
LT (1) LT3119431T (enExample)
MX (2) MX378344B (enExample)
PE (2) PE20161439A1 (enExample)
PL (1) PL3119431T3 (enExample)
PT (1) PT3119431T (enExample)
RS (1) RS65360B1 (enExample)
SI (1) SI3119431T1 (enExample)
SM (1) SMT202400131T1 (enExample)
UA (1) UA123759C2 (enExample)
WO (1) WO2015143409A1 (enExample)
ZA (1) ZA201606745B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
US11407838B2 (en) 2018-04-02 2022-08-09 Amgen Inc. Erenumab compositions and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
EP3920904A4 (en) * 2019-02-08 2022-11-09 Schedule 1 Therapeutics, Inc. COMPOSITIONS CONTAINING CANNABINOIDS AND METHODS OF USE THEREOF
BR112020027063A2 (pt) * 2019-05-02 2021-11-16 H Lundbeck As Tratamento de dor de cabeça com uso de anticorpos anti-cgrp
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
SG10202003296VA (en) * 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
WO2021243284A1 (en) * 2020-05-29 2021-12-02 Amgen Inc. Antibody formulations and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723039A (zh) * 2002-10-08 2006-01-18 里纳特神经系统学公司 通过施用神经生长因子拮抗剂治疗手术后疼痛的方法及包含其的组合物
CN102740884A (zh) * 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
WO2012161956A2 (en) * 2011-05-20 2012-11-29 Alder Biopharmaceuticals, Inc. High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris
CN103143016A (zh) * 2005-04-11 2013-06-12 礼纳特神经系统科学公司 通过给予神经生长因子拮抗剂及其组合物来治疗骨关节炎疼痛的方法
CN103421114A (zh) * 2005-11-14 2013-12-04 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
DE69034168T3 (de) 1989-03-21 2013-04-11 Vical, Inc. Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
AU620727B2 (en) 1989-07-10 1992-02-20 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU6524794A (en) 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
DK0695169T3 (da) 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0716148B1 (en) 1993-09-15 2004-01-02 Chiron Corporation Recombinant alphavirus vectors
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
WO1995013796A1 (en) 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
JPH07196700A (ja) 1994-01-06 1995-08-01 Sando Yakuhin Kk 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
ATE265466T1 (de) 1994-08-16 2004-05-15 Human Genome Sciences Inc Calcitoninrezeptor
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH11512396A (ja) 1995-09-05 1999-10-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP2002511836A (ja) 1996-09-09 2002-04-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JP3483893B2 (ja) 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
SE9704770D0 (sv) 1997-12-19 1997-12-19 Astra Ab New use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
AU6211499A (en) 1998-09-30 2000-04-17 Merck & Co., Inc. Benzimidazolinyl piperidines as cgrp ligands
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7097467B2 (en) 2002-06-03 2006-08-29 Wan-Tien Chen Dustproof plate fixture for an electrical connector
KR20050008790A (ko) 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
ES2323170T3 (es) 2002-08-12 2009-07-08 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para el tratamiento de la psoriasis.
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
CA2518830A1 (en) 2003-03-14 2004-09-30 Merck & Co., Inc. Carboxamide spirohydantoin cgrp receptor antagonists
AU2004222328B2 (en) 2003-03-14 2009-10-08 Merck Sharp & Dohme Corp. Aryl spirohydantoin CGRP receptor antagonists
ATE509019T1 (de) 2003-03-14 2011-05-15 Merck Sharp & Dohme Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
AU2004222383B2 (en) 2003-03-14 2009-10-01 Merck Sharp & Dohme Corp. Bicyclic anilide spirohydantoin CGRP receptor antagonists
US7192954B2 (en) 2003-03-14 2007-03-20 Merck & Co., Inc. Monocyclic anilide spirohydantoin CGRP receptor antagonists
EP1615914B1 (en) 2003-04-15 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
CN100418948C (zh) 2003-07-15 2008-09-17 麦克公司 羟基吡啶cgrp受体抗拮抗剂
WO2005041757A2 (en) 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1740175A1 (de) 2004-04-20 2007-01-10 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1928452A4 (en) 2005-08-25 2010-09-01 Wex Medical Ltd USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
US20070054843A1 (en) 2005-08-26 2007-03-08 Yeomans David C Methods for treatment of headaches by administration of oxytocin
WO2007035906A2 (en) 2005-09-21 2007-03-29 The Regents Of The University Of California Systems and methods for imaging-treatment of pain
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CA2629406A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
CA2658573A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
MX2010004488A (es) 2007-10-23 2010-06-17 Allergan Inc Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
CN106110321A (zh) 2008-03-04 2016-11-16 莱布瑞斯生物公司 治疗炎性疼痛的方法
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
CA2721950A1 (en) 2008-04-25 2009-10-29 Nellix, Inc. Stent graft delivery system
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
TWI692485B (zh) 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
KR102128628B1 (ko) 2011-05-20 2020-06-30 앨더바이오 홀딩스 엘엘씨 설사의 만성 및 급성 형태를 치료 또는 예방하기 위한 항-cgrp 또는 항-cgrp-r 항체 또는 항체 단편의 용도
TWI666318B (zh) 2011-08-19 2019-07-21 美商艾爾德生物控股有限責任公司 在經轉形的微生物如巴斯德畢赤氏酵母中的多－複製策略用於多－次級單元的蛋白質如抗體之高效價且高純度生產技術
KR20140111704A (ko) 2012-01-10 2014-09-19 녹손 파르마 아게 Cgrp에 특이적으로 결합하는 핵산
US8722060B2 (en) 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
WO2014067911A1 (en) 2012-10-29 2014-05-08 Net Entertainment Ne Ab Architecture for multi-player, multi-game, multi- table, multi-operator & multi-jurisdiction live casino gaming
DK2971037T3 (da) 2013-03-15 2019-10-14 Alder Biopharmaceuticals Inc Temperaturændring til ekspression med højt udbytte af polypeptider i gær og andre transformerede celler
US20160033504A1 (en) 2013-03-15 2016-02-04 Alder Biopharmaceuticals, Inc. Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
WO2015003122A2 (en) 2013-07-03 2015-01-08 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6956631B2 (ja) 2014-09-15 2021-11-02 アムジェン インコーポレイテッド 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP2018532728A (ja) 2015-09-24 2018-11-08 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー （持続性）外傷後頭痛の予防、治療および低減
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EA201990548A1 (ru) 2016-09-23 2019-09-30 Тева Фармасьютикалз Интернэшнл Гмбх Лечение кластерной головной боли
MA53436A (fr) 2018-08-22 2021-12-01 Lilly Co Eli Anticorps anti-cgrp pour patients résistants au traitement

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723039A (zh) * 2002-10-08 2006-01-18 里纳特神经系统学公司 通过施用神经生长因子拮抗剂治疗手术后疼痛的方法及包含其的组合物
CN103143016A (zh) * 2005-04-11 2013-06-12 礼纳特神经系统科学公司 通过给予神经生长因子拮抗剂及其组合物来治疗骨关节炎疼痛的方法
CN103421114A (zh) * 2005-11-14 2013-12-04 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
CN102740884A (zh) * 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
WO2012161956A2 (en) * 2011-05-20 2012-11-29 Alder Biopharmaceuticals, Inc. High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as pichia pastoris

Also Published As

Publication number Publication date
JP2021014464A (ja) 2021-02-12
US20190031745A1 (en) 2019-01-31
JP6568099B2 (ja) 2019-08-28
NZ761478A (en) 2024-01-26
WO2015143409A1 (en) 2015-09-24
JP2021121637A (ja) 2021-08-26
PE20220337A1 (es) 2022-03-14
US20150266948A1 (en) 2015-09-24
PT3119431T (pt) 2024-04-16
US9896502B2 (en) 2018-02-20
EA201691787A1 (ru) 2017-02-28
KR20200126018A (ko) 2020-11-05
LT3119431T (lt) 2024-03-12
CN106456759A (zh) 2017-02-22
ES2974803T3 (es) 2024-07-01
EP3119431B1 (en) 2024-01-24
JP2019123750A (ja) 2019-07-25
IL247853A0 (en) 2016-11-30
RS65360B1 (sr) 2024-04-30
HUE065397T2 (hu) 2024-06-28
HK1232129A1 (en) 2018-01-05
EP3119431A4 (en) 2017-09-06
UA123759C2 (uk) 2021-06-02
JP6892891B2 (ja) 2021-06-23
IL247853B (en) 2022-08-01
US11555064B2 (en) 2023-01-17
FI3119431T3 (fi) 2024-03-20
CN111973740A (zh) 2020-11-24
NZ724442A (en) 2021-02-26
HRP20240159T1 (hr) 2024-04-12
KR20240146107A (ko) 2024-10-07
KR102274964B1 (ko) 2021-07-09
IL294490A (en) 2022-09-01
SMT202400131T1 (it) 2024-05-14
ZA201606745B (en) 2022-12-21
JP2017510579A (ja) 2017-04-13
KR20160147755A (ko) 2016-12-23
DK3119431T3 (da) 2024-03-18
EP4324481A3 (en) 2024-05-01
PE20161439A1 (es) 2017-01-26
BR112016021423A2 (pt) 2017-11-14
EP3119431A1 (en) 2017-01-25
MX2020012816A (es) 2021-02-15
PL3119431T3 (pl) 2024-06-24
US20200331991A1 (en) 2020-10-22
CA2943551A1 (en) 2015-09-24
AU2015230933A1 (en) 2016-11-03
SI3119431T1 (sl) 2024-06-28
JP2024040245A (ja) 2024-03-25
AU2015230933B2 (en) 2020-08-13
US10519224B2 (en) 2019-12-31
MX378344B (es) 2025-03-10
EP4324481A2 (en) 2024-02-21
MX2016012188A (es) 2017-04-27
KR20220130822A (ko) 2022-09-27
CL2016002375A1 (es) 2017-05-19

Similar Documents

Publication Publication Date Title
US11555064B2 (en) Treating headache comprising administering an antibody to calcitonin gene-related peptide
US20230235032A1 (en) Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
CN101309704B (zh) 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
HK1225627A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide for treating cluster headache
HK1258385A1 (zh) 预防、治疗和减轻(持续性)创伤後头痛
HK40041381A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1233955A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
BR122020017648B1 (pt) Composição para o tratamento ou redução da incidência de enxaqueca compreendendo um anticorpo monoclonal que inibe a via do peptídeo relacionado ao gene da calcitonina
HK40051844A (en) Antagonist antibodies directed against calcitonin gene-related peptide
HK1227724A1 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1227724A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1125837B (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1190411A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
NZ724442B2 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HK1232129B (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination